Compare FOR & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | SVRA |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2007 | 2009 |
| Metric | FOR | SVRA |
|---|---|---|
| Price | $29.20 | $5.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $32.67 | $7.33 |
| AVG Volume (30 Days) | 126.8K | ★ 1.6M |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $1,662,400,000.00 | N/A |
| Revenue This Year | $0.34 | N/A |
| Revenue Next Year | $7.73 | $430.87 |
| P/E Ratio | $31.20 | ★ N/A |
| Revenue Growth | ★ 10.14 | N/A |
| 52 Week Low | $20.79 | $1.98 |
| 52 Week High | $30.74 | $7.01 |
| Indicator | FOR | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.14 | 66.88 |
| Support Level | $23.88 | $4.77 |
| Resistance Level | $30.74 | $6.15 |
| Average True Range (ATR) | 0.85 | 0.26 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 75.04 | 87.55 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).